The future of BRD9 inhibitors: a patent perspective (2019-present)

The patent landscape reflects a growing interest in BRD9 as an epigenetic target, e.g. for its key role in various pathologies. The recent patent data show how selective BRD9 degraders represent a significant step forward in terms of efficacy and selectivity, with promising results in preclinical models of acute myeloid leukemia (AML), synovial sarcoma (SS), and Huntington's disease (HD). Despite several critical issues, the selective degradation of this epigenetic target shows great potential to be an innovative therapeutic strategy.